00690.HK
Uni-Bio Science Group Limited
HKSE · Healthcare · Biotechnology · HK
HKD 0.06
+3.45%Year over year
Reported trailing growth
- Revenue
- +13.6%
- EBITDA
- -8.1%
- EBIT
- —
- EPS
- -9.7%
- Free cash flow
- -83.8%
- Operating cash flow
- -40.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +10.0%
- EBITDA
- +21.0%
- EBIT
- +33.2%
- Net income
- +34.3%
- EPS
- +36.8%
- Free cash flow
- +23.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026